The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem
A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2022-12, Vol.40 (12), p.1761-1763 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1763 |
|---|---|
| container_issue | 12 |
| container_start_page | 1761 |
| container_title | Nature biotechnology |
| container_volume | 40 |
| creator | Knox, Ryan Curfman, Gregory |
| description | A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle. |
| doi_str_mv | 10.1038/s41587-022-01583-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753316498</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2754337539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-5ad1801164ea249fd0063f7a74c3579aed9819bb734d61ad520b7295880bb1093</originalsourceid><addsrcrecordid>eNp9kL1OwzAUhS0EolB4AQYUiYWBgB3_JSOqgCJVwFAmBstJbiDQOMV2VLHxDky8Hk-CSyhIDAyWj3TP_e7RQWiP4GOCaXriGOGpjHGSxDgoGi_W0BbhTMREZGI9aLwcEy4GaNu5R4yxYEJsogEVTEqOyRa6mz5ANO6a2uporj0YH_mHungCfxQERFctWPvx-nYDxtTm3rcmKtvC29pApE0Znq-97Zz_eH13K8LctvkMmh20UemZg93vf4huz8-mo3E8ub64HJ1O4oJK7mOuS5JiQgQDnbCsKkNMWkktWUG5zDSUWUqyPJeUlYLokic4l0nG0xTnOcEZHaLDnhvuPnfgvGpqV8Bspg20nVOJ5JQGfJYG68Ef62PbWRPSLV2MhkB0CUx6V2Fb5yxUam7rRtsXRbBaVq_66lWoXn1VrxZhaf8b3eUNlD8rq66DgfYGF0bmHuzv7X-wnxf9kJc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754337539</pqid></control><display><type>article</type><title>The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem</title><source>MEDLINE</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Knox, Ryan ; Curfman, Gregory</creator><creatorcontrib>Knox, Ryan ; Curfman, Gregory</creatorcontrib><description>A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/s41587-022-01583-w</identifier><identifier>PMID: 36477501</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>706/689/159 ; 706/689/280 ; Adalimumab ; Agriculture ; Antitrust ; Bioinformatics ; Biological products ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Competition ; Decision making ; District courts ; FDA approval ; Federal court decisions ; First Amendment-US ; Life Sciences ; Litigation ; Market entry ; Petitions ; State court decisions</subject><ispartof>Nature biotechnology, 2022-12, Vol.40 (12), p.1761-1763</ispartof><rights>Springer Nature America, Inc. 2022</rights><rights>Springer Nature America, Inc. 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-5ad1801164ea249fd0063f7a74c3579aed9819bb734d61ad520b7295880bb1093</citedby><cites>FETCH-LOGICAL-c375t-5ad1801164ea249fd0063f7a74c3579aed9819bb734d61ad520b7295880bb1093</cites><orcidid>0000-0002-9157-9585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41587-022-01583-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41587-022-01583-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36477501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knox, Ryan</creatorcontrib><creatorcontrib>Curfman, Gregory</creatorcontrib><title>The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.</description><subject>706/689/159</subject><subject>706/689/280</subject><subject>Adalimumab</subject><subject>Agriculture</subject><subject>Antitrust</subject><subject>Bioinformatics</subject><subject>Biological products</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Competition</subject><subject>Decision making</subject><subject>District courts</subject><subject>FDA approval</subject><subject>Federal court decisions</subject><subject>First Amendment-US</subject><subject>Life Sciences</subject><subject>Litigation</subject><subject>Market entry</subject><subject>Petitions</subject><subject>State court decisions</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kL1OwzAUhS0EolB4AQYUiYWBgB3_JSOqgCJVwFAmBstJbiDQOMV2VLHxDky8Hk-CSyhIDAyWj3TP_e7RQWiP4GOCaXriGOGpjHGSxDgoGi_W0BbhTMREZGI9aLwcEy4GaNu5R4yxYEJsogEVTEqOyRa6mz5ANO6a2uporj0YH_mHungCfxQERFctWPvx-nYDxtTm3rcmKtvC29pApE0Znq-97Zz_eH13K8LctvkMmh20UemZg93vf4huz8-mo3E8ub64HJ1O4oJK7mOuS5JiQgQDnbCsKkNMWkktWUG5zDSUWUqyPJeUlYLokic4l0nG0xTnOcEZHaLDnhvuPnfgvGpqV8Bspg20nVOJ5JQGfJYG68Ef62PbWRPSLV2MhkB0CUx6V2Fb5yxUam7rRtsXRbBaVq_66lWoXn1VrxZhaf8b3eUNlD8rq66DgfYGF0bmHuzv7X-wnxf9kJc</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Knox, Ryan</creator><creator>Curfman, Gregory</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9157-9585</orcidid></search><sort><creationdate>20221201</creationdate><title>The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem</title><author>Knox, Ryan ; Curfman, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-5ad1801164ea249fd0063f7a74c3579aed9819bb734d61ad520b7295880bb1093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>706/689/159</topic><topic>706/689/280</topic><topic>Adalimumab</topic><topic>Agriculture</topic><topic>Antitrust</topic><topic>Bioinformatics</topic><topic>Biological products</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Competition</topic><topic>Decision making</topic><topic>District courts</topic><topic>FDA approval</topic><topic>Federal court decisions</topic><topic>First Amendment-US</topic><topic>Life Sciences</topic><topic>Litigation</topic><topic>Market entry</topic><topic>Petitions</topic><topic>State court decisions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knox, Ryan</creatorcontrib><creatorcontrib>Curfman, Gregory</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knox, Ryan</au><au>Curfman, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>40</volume><issue>12</issue><spage>1761</spage><epage>1763</epage><pages>1761-1763</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>A recent federal appellate court decision will make challenging future pharmaceutical ‘patent thickets’ an uphill battle.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>36477501</pmid><doi>10.1038/s41587-022-01583-w</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-9157-9585</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2022-12, Vol.40 (12), p.1761-1763 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753316498 |
| source | MEDLINE; Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | 706/689/159 706/689/280 Adalimumab Agriculture Antitrust Bioinformatics Biological products Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Competition Decision making District courts FDA approval Federal court decisions First Amendment-US Life Sciences Litigation Market entry Petitions State court decisions |
| title | The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T01%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Humira%20patent%20thicket,%20the%20Noerr%E2%80%93Pennington%20doctrine%20and%20antitrust%E2%80%99s%20patent%20problem&rft.jtitle=Nature%20biotechnology&rft.au=Knox,%20Ryan&rft.date=2022-12-01&rft.volume=40&rft.issue=12&rft.spage=1761&rft.epage=1763&rft.pages=1761-1763&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/s41587-022-01583-w&rft_dat=%3Cproquest_cross%3E2754337539%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754337539&rft_id=info:pmid/36477501&rfr_iscdi=true |